The accumulation of amyloid-beta plaques in the cerebral cortex during Alzheimer's disease (AD) is only one outcome of the proteolytic cleavage of amyloid precursor protein (APP). Over 50 different mutations in the APP gene increase the chances of amyloid-beta plaque generation, leading to early-onset AD. Cleavage of mutated APP by beta-secretase (BACE1) then gamma-secretase—the amyloidogenic pathway—leads to production of pathologic, insoluble amyloid-beta deposits as well as non-pathologic, soluble APP-beta (sAPP-beta), while cleavage by alpha-secretase—the nonamyloidogenic pathway—results in only non-pathogenic sAPP-alpha.
Alpha2 6-sialyltransferase (ST6Gal I) is a glycosyltransferase involved in the biosynthesis of sugar chains. ST6Gal I catalyzes the transfer of an alpha-2,6-linked sialic acid to the N-glycans of certain receptors. Studies have shown that ST6Gal I is cleaved by BACE1, both in vitro and in vivo, to produce a peptide known as ST6Gal I (E41 Form). In humans, cleavage of ST6Gal I by BACE1 generates alpha-2,6-sialyltransferase (E44 form), while in rats it generates alpha-2,6-sialyltransferase (E41 form).
Alternative names: alpha-2,6-ST1, CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 1, sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase), beta-galactoside alpha-2,6-sialyltransferase 1, sialyltransferase 1, 1ST6N, and SIAT1.
ELISAs for Alpha-2,6-Sialyltransferase Detection
These kits are solid-phase sandwich ELISAs using antibodies that are highly specific to human, mouse, and rat ST6Gal I (Cat. # 27762A) or the E41 form in rat (Cat. # 27408A). These ELISAs can be used to measure ST6Gal I in serum, EDTA plasma, or cell culture supernatant.
Antibodies for Alpha-2,6-Sialyltransferase Detection
The ST6Gal I antibody products are an affinity-purified antibodies raised in rabbit using synthetic peptides that recognize ST6Gal I protein. These antibodies and can be used for Western blot (WB) detection of ST6Gal I protein.